ACE inhibitors potently reduce vascular inflammation, results of an open proof-of-concept study in the abdominal aortic aneurysm

PLoS ONE

Volumn 9, Issue 12, 2014, Pages

  Kortekaas, Kim E ^a,b   Meijer, C Arnoud ^a   Hinnen, Jan Willem ^a,c   Dalman, Ronald L ^b   Xu, Baohui ^b   Hamming, Jaap F ^a   Lindeman, Jan H ^a  

^a LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

^b STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c JEROEN BOSCH HOSPITAL   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

DOXYCYCLINE; GAMMA INTERFERON; INTERLEUKIN 1BETA; INTERLEUKIN 6; INTERLEUKIN 8; MESSENGER RNA; MONOCYTE CHEMOTACTIC PROTEIN 1; RAMIPRIL; TUMOR NECROSIS FACTOR ALPHA; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR;

ABDOMINAL AORTA ANEURYSM; ADULT; AGED; ANTIINFLAMMATORY ACTIVITY; ARTICLE; CASE CONTROL STUDY; CLINICAL ARTICLE; COHORT ANALYSIS; CONTROLLED STUDY; DISEASE COURSE; FEMALE; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MACROPHAGE ACTIVATION; MALE; PROTEIN ANALYSIS; RETROSPECTIVE STUDY; VASCULITIS; AORTA; AORTIC ANEURYSM, ABDOMINAL; BIOSYNTHESIS; BLOOD VESSEL; DRUG EFFECTS; GENE EXPRESSION REGULATION; INFLAMMATION; MACROPHAGE; METABOLISM; MIDDLE AGED; PATHOLOGY; PATHOPHYSIOLOGY;

AGED; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; AORTA; AORTIC ANEURYSM, ABDOMINAL; BLOOD VESSELS; FEMALE; GENE EXPRESSION REGULATION; HUMANS; INFLAMMATION; INTERLEUKIN-6; INTERLEUKIN-8; MACROPHAGES; MALE; MIDDLE AGED; RAMIPRIL; RNA, MESSENGER;

EID: 84915751800     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0111952     Document Type: Article

References (42)

1. Krysiak R, Okopien B (2008) Pleiotropic effects of angiotensin-converting enzyme inhibitors in normotensive patients with coronary artery disease. Pharmacol Rep 60: 514-523.
2. Montecucco F, Pende A, Mach F (2009) The renin-angiotensin system modulates inflammatory processes in atherosclerosis: evidence from basic research and clinical studies. Mediators Inflamm 2009: 752406.
3. Xiong F, Zhao J, Zeng G, Huang B, Yuan D, et al. (2014) Inhibition of AAA in a rat model by treatment with ACEI perindopril. J Surg Res 189: 166-73.
4. Ruiz-Ortega M, Lorenzo O, Ruperez M, Egido J (2000) ACE inhibitors and AT(1) receptor antagonistsbeyond the haemodynamic effect. Nephrol Dial Transplant 15: 561-5.
5. Osborne-Pellegrin MJ, Coutard M, Poitevin P, Michel JB, Levy BI (1994) Induction of aneurysms in the rat by a stenosing cotton ligature around the inter-renal aorta. Int J Exp Pathol 75: 179-90.
6. da Cunha V, Tham DM, Martin-McNulty B, Deng G, Ho JJ, et al. (2005) Enalapril attenuates angiotensin II induced atherosclerosis and vascular inflammation. Atherosclerosis 178: 9-17.
7. Liao S, Miralles M, Kelley BJ, Curci JA, Borhani M, et al. (2001) Suppression of experimental abdominal aortic aneurysms in the rat by treatment with angiotensin converting enzyme inhibitors. J Vasc Surg 33: 1057-1064.
8. Di Raimondo D, Tuttolomondo A, Butta C, Miceli S, Licata G, et al. (2012) Effects of ACE-inhibitors and angiotensin receptor blockers on inflammation. Curr Pharm Des 18: 4385-4413.
9. Rizas KD, Ippagunta N, Tilson MD 3rd (2009) Immune cells and molecular mediators in the pathogenesis of the abdominal aortic aneurysm. Cardiol Rev 17: 201-210.
10. Lindeman JH, Abdul-Hussien H, Schaapherder AF, van Bockel JH, von der Thüsen JH, et al. (2008) Enhanced expression and activation of pro-inflammatory transcription factors distinguish aneurysmal from atherosclerotic aorta: IL-6- and IL-8-dominated inflammatory responses prevail in the human aneurysm. Clin Sci (Lond) 114: 687-697.
11. Cornuz J, Sidoti Pinto C, Tevaearai H, Egger M (2004) Risk factors for asymptomatic abdominal aortic aneurysm: systematic review and meta-analysis of population-based screening studies. Eur J Public Health 14: 343-9.
12. Thompson SG, Brown LC, Sweeting MJ, Bown MJ, Kim LG, et al. (2013) Systematic review and meta-analysis of the growth and rupture rates of small abdominal aortic aneurysms: implications for surveillance intervals and their cost-effectiveness. Health Technol Assess 17: 1-118.
13. Thompson RW, Curci JA, Ennis TL, Mao D, Pagano MB, et al. (2006) Pathophysiology of abdominal aortic aneurysms: insights from the elastase-induced model in mice with different genetic backgrounds. Ann N Y Acad Sci 1085: 59-73.
14. Hackam DG, Thiruchelvam D, Redelmeier DA (2006) Angiotensin-converting enzyme inhibitors and aortic rupture: a population-based case-control study. Lancet. 2006; 368: 659-65.
15. Wilmink AB, Vardulaki KA, Hubbard CS, Day NE, Ashton HA, et al. (2002) Are antihypertensive drugs associated with abdominal aortic aneurysms? J Vasc Surg 36: 751-7.
16. Sweeting MJ, Thompson SG, Brown LC, Greenhalgh RM, Powell JT (2010) Use of angiotensin converting enzyme inhibitors is associated with increased growth rate of abdominal aortic aneurysms. J Vasc Surg 52: 1-4.
17. Meijer CA, Stijnen T, Wasser MNJM, Hamming JF, van Bockel JH, et al. (2013) Doxycycline for stabilization of abdominal aortic aneurysms: a randomized trial. Ann Intern Med 159: 815-823.
18. Zwadlo G, Voegeli R, Schulze Osthoff K, Sorg C (1987) A monoclonal antibody to a novel differentiation antigen on human macrophages associated with the down-regulatory phase of the inflammatory process. Exp Cell Biol 55: 295-304.
19. Mukhtar RA, Nseyo O, Campbell MJ, Esserman LJ (2011) Tumor-associated macrophages in breast cancer as potential biomarkers for new treatments and diagnostics. Expert Rev Mol Diagn 11: 91-100.
20. Luoma JS, Stralin P, Marklund SL, Hiltunen TP, Sarkioja T, et al. (1998) Expression of extracellular SOD and iNOS in macrophages and smooth muscle cells in human and rabbit atherosclerotic lesions: colocalization with epitopes characteristic of oxidized LDL and peroxynitrite-modified proteins. Arterioscler Thromb Vasc Biol 18: 157-167.
21. van der Meij E, Koning GG, Vriens PW, Peeters MF, Meijer CA, et al. (2013) A clinical evaluation of statin pleiotropy: statins selectively and dose-dependently reduce vascular inflammation. PLoS One 8: 53882.
22. Haslinger B, Kleemann R, Toet KH, Kooistra T (2003) Simvastatin suppresses tissue factor expression and increases fibrinolytic activity in tumor necrosis factor-alpha-activated human peritoneal mesothelial cells. Kidney Int 63: 2065-2074.
23. Abdul-Hussien H, Soekhoe RG, Weber E, von der Thüsen JH, Kleemann R, et al. (2007) Collagen degradation in the abdominal aneurysm: a conspiracy of matrix metalloproteinase and cysteine collagenases. Am J Pathol 170: 809-817.
24. Fitzmaurice GM, Ravichandran C (2008) A primer in longitudinal data analysis. Circulation 118: 2005-2010.
25. Lindeman JH, Abdul-Hussien H, van Bockel JH, Wolterbeek R, Kleemann R (2009) Clinical trial of doxycycline for matrix metalloproteinase-9 inhibition in patients with an abdominal aneurysm: doxycycline selectively depletes aortic wall neutrophils and cytotoxic Tcells. Circulation 119: 2209-2216.
26. Bender N, Rangoonwala B, Rosenthal J, Vasmant D (1990) Physicochemical and enzyme binding kinetic properties of a new angiotensin-converting enzyme inhibitor ramipril and their clinical implications. Clin Physiol Biochem 8 Suppl 1: 44-52.
27. Ferrari R, Fox K (2009) Insight into the mode of action of ACE inhibition in coronary artery disease: the ultimate 'EUROPA' story. Drugs 69: 265-277.
28. Hernandez-Presa MA, Bustos C, Ortego M, Tunon J, Ortega L, et al. (1998) ACE inhibitor quinapril reduces the arterial expression of NF-kappaB-dependent proinflammatory factors but not of collagen I in a rabbit model of atherosclerosis. Am J Pathol 153: 1825-1837.
29. Elewaut D, DiDonato JA, Kim JM, Truong F, Eckmann L, et al. (1999) NF-kappa B is a central regulator of the intestinal epithelial cell innate immune response induced by infection with enteroinvasive bacteria. J Immunol 163: 1457-66.
30. Schmeisser A, Soehnlein O, Illmer T, Lorenz HM, Eskafi S, et al. (2004) ACE inhibition lowers angiotensin II induced chemokine expression by reduction of NF-kappaB activity and AT1 receptor expression. Biochem Biophys Res Commun 325: 532-540.
31. Soehnlein O, Schmeisser A, Cicha I, Reiss C, Ulbrich H, et al. (2005) ACE inhibition lowers angiotensin-II-induced monocyte adhesion to HUVEC by reduction of p65 translocation and AT 1 expression. J Vasc Res 42: 399-407.
32. Hernandez-Presa M, Bustos C, Ortego M, Tuñon J, Renedo G, et al. (1997) Angiotensin-converting enzyme inhibition prevents arterial nuclear factor-kappa B activation, monocyte chemoattractant protein- 1 expression, and macrophage infiltration in a rabbit model of early accelerated atherosclerosis. Circulation 95: 1532-1541.
33. Kowalewski R, Sobolewski K, Malkowski A, Wolanska M, Gacko M (2006) Evaluation of enzymes involved in proteoglycan degradation in the wall of abdominal aortic aneurysms. J Vasc Res 43: 95-100.
34. Liu J, Sukhova GK, Yang JT, Sun J, Ma L, et al. (2006) Cathepsin L expression and regulation in human abdominal aortic aneurysm, atherosclerosis, and vascular cells. Atherosclerosis 184: 302-311.
35. Watanabe T, Sato A, Sawai T, Uzuki M, Goto H, et al. (2006) The elevated level of circulating matrix metalloproteinase-9 in patients with abdominal aortic aneurysms decreased to levels equal to those of healthy controls after an aortic repair. Ann Vasc Surg 20: 317-321.
36. McMillan WD, Pearce WH (1999) Increased plasma levels of metalloproteinase-9 are associated with abdominal aortic aneurysms. J Vasc Surg 29: 122-127.
37. Yoshimura K, Aoki H (2012) Recent advances in pharmacotherapy development for abdominal aortic aneurysm. Int J Vasc Med 2012: 648167.
38. Yang F, Chung AC, Huang XR, Lan HY (2009) Angiotensin II induces connective tissue growth factor and collagen I expression via transforming growth factor-beta-dependent and -independent Smad pathways: the role of Smad3. Hypertension 54: 877-884.
39. Goemann JJ, Solari A (2011) Multiple Testing for Exploratory Research. Statistical Science 26: 584-597.
40. Lindeman JH, Rabelink TJ, van Bockel JH (2011) Immunosuppression and the abdominal aortic aneurysm: Doctor Jekyll or Mister Hyde? Circulation 2011; 124: 463-5.
41. Lederle F (2013) Abdominal Aortic Aneurysm: Still No Pill. Ann Intern Med 159: 852-853.
42. Law MR, Morris JK, Wald NJ (2009) Use of blood pressure lowering drugs in the prevention of cardiovascular disease: meta-analysis of 147 randomised trials in the context of expectations from prospective epidemiological studies. BMJ 338: b1665.